Gilead Sciences
GILD
$131.40
+1.21%
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening infectious diseases, with a core portfolio focused on HIV and hepatitis B and C, and a growing presence in oncology through acquisitions like Kite and Immunomedics. It is a dominant player in the HIV market and a significant competitor in oncology, leveraging its commercial infrastructure and pipeline to drive growth. The current investor narrative centers on Gilead's aggressive acquisition strategy to bolster its oncology and inflammation pipelines, including the $7.8 billion Arcellx deal and the $3 billion Tubulis acquisition, while navigating mixed clinical trial results and the impact of drug tariffs.…
GILD
Gilead Sciences
$131.40
Related headlines
Investment Opinion: Should I buy GILD Today?
Rating: Buy. Gilead offers a compelling risk/reward with a forward P/E of 13.5x, a 36% upside to the implied analyst target of ~$177, and a strong balance sheet. The consensus analyst rating is Buy, supported by recent upgrades from Needham, Truist, and UBS.
Supporting evidence: (1) Forward P/E of 13.5x is a 39% discount to the sector median of ~22x. (2) Revenue growth of 4.7% YoY is modest but accelerating from prior quarters. (3) Operating margin expanded to 37.4% in Q4 2025 from 32.4% a year ago. (4) Free cash flow of $9.455 billion covers the dividend (yield 2.6%) and acquisition spending. The PEG ratio of 0.01 suggests deep undervaluation relative to expected EPS growth of 33%.
Risks & Conditions: The thesis could be invalidated if (1) revenue growth decelerates below 2% due to HIV competition, (2) acquisition integration fails to deliver pipeline milestones, or (3) drug tariffs materially impact costs. This Buy would downgrade to Hold if the stock reaches $160 (near analyst target) without new catalysts, or to Sell if forward P/E expands above 18x without earnings growth. Overall, Gilead appears undervalued relative to its history and peers.
Sign up to view all
GILD 12-Month Price Forecast
Gilead's valuation is compelling at 13.5x forward earnings, with strong cash flows and margin expansion supporting the bull case. However, modest revenue growth and acquisition risks warrant medium confidence. The base case of 4-5% growth and stable margins is most likely, but successful pipeline execution could drive upside toward $177. Downside risks from competition and tariffs are manageable given the low beta and strong balance sheet. An upgrade to high confidence would require sustained revenue acceleration above 6%, while a downgrade would follow a failed Phase 3 trial.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $170.82 and implied upside of +30.0% versus the current price.
Average Target
$170.82
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$105 - $171
Analyst target range
Gilead is covered by 11 analysts, with a consensus leaning bullish. The average target price is not explicitly provided, but based on the estimated EPS of $13.11 and a forward P/E of 13.5x, the implied target is approximately $177. This would represent 36% upside from the current price of $129.83. The consensus recommendation is likely a Buy, given the recent ratings from Needham (Buy), Truist (Buy), and UBS (Buy). The estimated EPS range is $12.69 to $13.74, and revenue estimates range from $37.8 billion to $40.2 billion, indicating moderate uncertainty. The high target of $13.74 EPS assumes successful pipeline execution and margin expansion, while the low target of $12.69 EPS prices in competitive pressures and R&D costs. Recent institutional ratings show no downgrades, with firms like Needham and Truist reiterating Buy ratings in February 2026, suggesting stable sentiment. The wide spread in EPS estimates (8% range) reflects uncertainty around pipeline success and acquisition integration, but the overall bullish consensus indicates confidence in Gilead's strategic direction.
Bulls vs Bears: GILD Investment Factors
Gilead presents a mixed picture: strong profitability and cash flow support a solid foundation, but decelerating revenue growth and acquisition risks temper enthusiasm. The bull case rests on attractive forward valuation (13.5x P/E) and pipeline expansion via M&A, while the bear case highlights integration risk, modest organic growth, and tariff uncertainty. Currently, the bull side has slightly stronger evidence given the deep valuation discount and robust free cash flow, but the key tension is whether the oncology pipeline can deliver enough growth to offset HIV market maturation and justify the current multiple.
Bullish
- Strong Profitability and Cash Flow: Gilead's Q4 2025 net margin was 27.5% and operating margin expanded to 37.4% from 32.4% a year ago. Free cash flow (TTM) of $9.455 billion provides ample capacity for acquisitions and dividends.
- Attractive Forward Valuation: Forward P/E of 13.5x is a 39% discount to the sector median of ~22x. The PEG ratio of 0.01 suggests the stock is deeply undervalued relative to expected earnings growth.
- Robust HIV and Oncology Growth: HIV product revenue reached $5.8 billion in Q4 2025, and cell therapy contributed $627 million. Oncology segment (Trodelvy at $383 million) provides a new growth vector.
- Aggressive Pipeline Expansion via M&A: Recent acquisitions of Arcellx ($7.8B), Tubulis ($3B), and Ouro Medicines ($1.5B) strengthen oncology and inflammation pipelines, with Arcellx's CAR-T therapy expected to boost earnings from 2028.
Bearish
- Decelerating Revenue Growth: Q4 2025 revenue grew only 4.7% YoY, down from prior quarters. The 1-year price return of +13.3% underperformed the S&P 500's +20.6%, indicating market skepticism about growth prospects.
- High Debt and Acquisition Risk: Debt-to-equity ratio of 1.08 is elevated, and the $7.8B Arcellx acquisition at a 68% premium adds integration risk. Failed Trodelvy-Keytruda lung cancer trial highlights R&D execution risk.
- Valuation Compression Risk: Trailing P/E of 17.9x is near the middle of its 5-year range (10x-26x), but the stock's beta of 0.34 limits upside in bull markets. Relative strength over 3 months is -17.7% vs. S&P 500.
- Drug Tariff and Regulatory Headwinds: New 100% tariff on imported drugs could impact Gilead's supply chain. The company's exemption status is unclear, posing a potential cost headwind.
GILD Technical Analysis
Gilead's stock is in a range-bound consolidation phase, with a 1-year price change of +13.3%, underperforming the S&P 500's 20.6% gain. The current price of $129.83 sits at 62% of its 52-week range ($107.75 to $157.29), indicating it is closer to the midpoint than extremes, suggesting neither overbought nor oversold conditions. The stock's beta of 0.34 implies it is significantly less volatile than the market, which may appeal to risk-averse investors but also limits upside participation in strong market rallies. Short-term momentum shows a divergence: the 1-month change is +6.9%, while the 3-month change is -6.6%, indicating a recent bounce from a pullback. This short-term strength contrasts with the longer-term 1-year trend, suggesting a potential mean reversion or temporary recovery rather than a sustained trend reversal. The relative strength index (RSI) is not directly provided, but the price action from the 52-week low suggests a recovery attempt. Key support is at the 52-week low of $107.75, while resistance is at the 52-week high of $157.29. A breakout above $157.29 would signal a resumption of the uptrend, while a breakdown below $107.75 could indicate further downside. With a beta of 0.34, Gilead is 66% less volatile than the S&P 500, meaning it tends to decline less in market downturns but also rallies less in up markets, which is typical for a large-cap pharma stock.
Beta
0.34
0.34x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+19.8%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +1.0% |
| 3m | -6.4% | +7.9% |
| 6m | +5.9% | +8.5% |
| 1y | +19.8% | +20.1% |
| ytd | +8.1% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory is modestly growing, with Q4 2025 revenue of $7.925 billion, up 4.7% year-over-year from $7.569 billion in Q4 2024. The multi-quarter trend shows sequential growth from $6.667 billion in Q1 2025 to $7.925 billion in Q4 2025, driven by HIV products ($5.8 billion in Q4) and cell therapy ($627 million), though Veklury sales declined to $211 million. The growth rate is decelerating from the 2024 levels, but the oncology segment (Trodelvy at $383 million) provides a new growth vector. The company is highly profitable, with Q4 2025 net income of $2.183 billion and a gross margin of 86.8%, which is strong for the pharma industry. Operating margin was 37.4% in Q4 2025, up from 32.4% in Q4 2024, indicating margin expansion due to cost control and product mix. The net margin of 27.5% is robust, though it fluctuates due to acquisition-related charges. Gilead's balance sheet is solid, with a debt-to-equity ratio of 1.08 and a current ratio of 1.68, indicating adequate liquidity. Free cash flow (TTM) is $9.455 billion, providing ample capacity for acquisitions and dividends. The ROE of 37.5% is exceptional, reflecting efficient capital use, though the high payout ratio of 47% suggests a commitment to returning capital to shareholders.
Quarterly Revenue
$7.9B
2025-12
Revenue YoY Growth
+4.70%
YoY Comparison
Gross Margin
86.84%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Since net income is positive ($2.183 billion in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 17.9x, while the forward P/E is 13.5x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests an anticipated 33% earnings increase, which is aggressive given the modest revenue growth. Compared to the industry average (Drug Manufacturers - General), Gilead's trailing P/E of 17.9x is at a discount to the sector median of approximately 22x (based on typical pharma valuations), representing a 19% discount. This discount may be justified by Gilead's slower revenue growth relative to high-growth biotechs, but its strong profitability and cash flow support a premium. Historically, Gilead's trailing P/E has ranged from 10x to 26x over the past five years. The current 17.9x is near the middle of this range, suggesting fair valuation. The P/E was as low as 5.4x in Q1 2024 (due to a loss) and as high as 26.5x in Q1 2025, so the current level is not extreme. The P/S ratio of 5.2x is also below the 5-year average of ~14x, indicating potential undervaluation on a sales basis.
PE
17.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~982x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's debt-to-equity ratio of 1.08 is moderate but elevated after recent acquisitions. The company's net income is robust at $2.183 billion in Q4 2025, but the trailing P/E of 17.9x implies the market expects continued earnings growth. Revenue growth of only 4.7% YoY is modest, and the high payout ratio of 47% limits retained capital for organic investment. Free cash flow of $9.455 billion provides a cushion, but any disruption to HIV sales (which dominate revenue) could pressure margins.
Market & Competitive Risks: Gilead's beta of 0.34 indicates low market correlation, but the stock has underperformed the S&P 500 over 1 year (+13.3% vs. +20.6%). The forward P/E of 13.5x is a discount to the sector, but this could compress further if growth disappoints. Competitive threats in HIV and oncology are significant, with new therapies from Merck and others. The 100% drug tariff poses a regulatory risk, and the failed Trodelvy-Keytruda trial highlights clinical development uncertainty.
Worst-Case Scenario: A combination of failed pipeline trials (e.g., Arcellx CAR-T), HIV revenue decline due to competition, and integration issues from acquisitions could drive the stock to its 52-week low of $107.75, representing a 17% downside from the current price of $129.83. In a severe recession, the stock could fall further, but the low beta limits downside relative to the market. Historical max drawdown of -22% suggests a potential loss of ~$28.56 per share from current levels.
FAQ
The key risks are: (1) Pipeline failure – the $7.8B Arcellx acquisition and other oncology bets may not deliver expected returns, as seen with the failed Trodelvy-Keytruda trial. (2) HIV competition – new therapies from Merck and others could erode Gilead's dominant market share, pressuring revenue. (3) Drug tariffs – the 100% tariff on imported drugs could increase costs if Gilead is not exempt. (4) Integration risk – the multiple acquisitions (Arcellx, Tubulis, Ouro) may strain management and dilute earnings. The most severe risk is a pipeline setback that undermines the growth narrative, potentially driving the stock to its 52-week low of $107.75.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading between $140 and $157, driven by 4-5% revenue growth and stable margins. The bull case (25% probability) targets $157-$177 on successful pipeline catalysts, while the bear case (25% probability) sees $108-$130 on setbacks. The implied analyst target of ~$177 suggests 36% upside. The most likely scenario is the base case, assuming HIV sales hold steady and oncology grows modestly. Key catalysts include Arcellx data and HIV market share trends.
Gilead appears undervalued relative to both its history and peers. The trailing P/E of 17.9x is near the middle of its 5-year range (10x-26x), but the forward P/E of 13.5x implies the market expects significant earnings growth. Compared to the Drug Manufacturers sector median P/E of ~22x, Gilead trades at a 39% discount. The P/S ratio of 5.2x is also below the 5-year average of ~14x. This valuation suggests the market is pricing in modest growth and high execution risk, which may be overly pessimistic given the company's strong cash flows and pipeline potential.
Gilead is a good buy for value-oriented investors seeking a low-beta, income-generating stock with upside potential. The forward P/E of 13.5x is a 39% discount to the sector median, and the implied analyst target of ~$177 offers 36% upside. However, revenue growth is modest at 4.7% YoY, and acquisition integration risks exist. The stock is best suited for long-term investors who can tolerate pipeline uncertainty in exchange for a 2.6% dividend yield and strong free cash flow. Short-term traders may find the low beta and range-bound price action less attractive.
Gilead is better suited for long-term investment due to its low beta (0.34), stable dividend (2.6% yield), and pipeline catalysts that take years to materialize. The stock's 1-year return of +13.3% underperformed the S&P 500, and its range-bound price action makes it less attractive for short-term trading. A minimum holding period of 3-5 years is recommended to allow pipeline assets (e.g., Arcellx CAR-T) to contribute to earnings. Short-term traders may find limited volatility, but the 6.9% 1-month gain suggests occasional tactical opportunities.